Found 144 results in Expert Content

Summary: Learn more about orally disintegrating tablets as a solution to various factors that impact treatment adherence rates across various diseases.

An advanced development offering that integrates formulation expertise with on-demand Phase 1 clinical manufacturing, adaptive clinical testing and regulatory support, to help achieve flexible and efficient First-in-Human studies and expedited development.

Summary: Experts provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon.

Summary: In this webinar, experts provide an overview of the needs of different patient populations and examine the common challenges leading to non-compliance.

Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly characterised using multiple material-sparing assays, allowing the most promising formulation candidates to move on to in vivo studies.

This article looks at how innovation in the industry-leading Zydis ODT platform is expanding oral formulation options and bringing benefits to patients.

Summary: Using Zydis® orally dissolving tablet (ODT) platform from Catalent as a unique delivery route for allergy immunotherapies.

Summary: Learn more about the role of oral dose delivery for tolerogenic vaccines, fast dissolving tablets and biological APIs.

Summary: While new drug products may benefit from ODT formulation beginning with product launch, ODT formulation can also play a role in life cycle management of approved products.

OptiForm® Solution Suite Bio is designed to rapidly screen biomolecules’ potential for a non-invasive delivery route.